ILMN Illumina, Inc.

295.031.64 (+0.56%)
IEX price: 3:59:55 PM

Quote

Previous Close
-
Day Range
-
52 Week Range
$263.30-$380.76
Volume
741,635
Avg Volume
992,894
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$43.37B
Enterprise Value (EV)
$41.61B
PE Ratio
44.56
EV/EBITDA
39.18
Price/Sales
12.94
Price/Book
11.54
PEG Ratio
1.65

Financials

Revenue
$3.33B
Gross Profit
$2.33B
EBITDA
$1.06B
EPS, ttm
$6.62
Profit Margin
24.78%
Revenue/Employee
$456.58K
Next Earnings Date
2/4/2020 (85 days)
Debt to Equity
53%
Debt
$1.76B
Cash
$3.51B
Net Debt
-

Performance

Beta
1.42
200 Day Moving Avg
$308.72
50 Day Moving Avg
$297.48
52 Week Change
-10.89%
YTD Change
0.18%
1 Month Change
1.74%
3 Month Change
-1.69%
6 Month Change
-8.15%
1 Year Change
-13.59%
2 Year Change
38.92%
5 Year Change
55.83%

Share Count

Shares Outstanding
147.0M
Float
146.4M
Restricted Shares
563.0K
Restricted Shares, %
0.38%

Illumina, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Francis A. deSouza

Website: http://www.illumina.com

Description: Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Employees: 7,300